Animal Health

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

A deadly, vaccine-less Ebola strain is spreading in Central Africa. As governments scramble, the CDC Foundation deploys its most potent weapon: agile funding.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

South Korea's Dong Bang Co Ltd is moving beyond commodity animal drugs, targeting high-barrier markets. Is its focus on proprietary tech a viable global strategy?

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Advocacy groups demand a congressional audit, alleging the BLM's sales program creates an unregulated pipeline for slaughtering protected wild horses.

Chinese vaccine maker Zhengye Biotechnology has 180 days to save its Nasdaq listing. But the sub-$1 stock price is just a symptom of deeper financial decay.

A year into a landmark partnership with AI firm VetRec, NC State's vet school shows how student-led tech adoption is freeing clinicians for what matters most.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Beyond greenwashing, the animal health giant's latest report reveals a calculated strategy where innovation, philanthropy, and climate action drive market leadership.

The world's largest veterinary conference, VMX 2027, confronts industry burnout with its 'Off the Grid' theme, blending professional renewal with science.

Parnell's new Sevoflurane offering is more than a product line extension; it's a strategic move to become a one-stop-shop for veterinary anesthesia.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

A $3.1B company's partnership with a local wildlife center is more than charity; it's a blueprint for how corporations are embedding social value into their strategy.

PBI-Gordon's strategic hire of Kent Luther for Pegasus Labs signals a major push in animal health, blending big pharma talent with an employee-owned model.